Publications by authors named "Danielle Renfrey"
Background: With increasing recognition of the value of incorporating prognostic markers into amyotrophic lateral sclerosis (ALS) trial design and analysis plans, there is a pressing need to understand which among the prevailing clinical and biochemical markers have real value, and how they can be optimally used.
Methods: A subset of patients with ALS recruited through the multi-center Phenotype-Genotype-Biomarker study (clinicaltrials.gov: NCT02327845) was identified as "trial-like" based on meeting common trial eligibility criteria.
Background: With increasing recognition of the value of incorporating prognostic markers into amyotrophic lateral sclerosis (ALS) trial design and analysis plans, there is a pressing need to understand among the prevailing clinical and biochemical markers have real value, and they can be optimally used.
Methods: A subset of patients with ALS recruited through the multi-center Phenotype-Genotype-Biomarker study (clinicaltrials.gov: NCT02327845) was identified as "trial-like" based on meeting common trial eligibility criteria.
Article Synopsis
- Healthcare facilities generate large amounts of waste, particularly from diagnostic plastics, prompting the need for more sustainable solutions.
- A new detection platform replaces traditional assay plates with a membrane in a portable device, enabling faster and greener detection of the p75 biomarker associated with ALS prognosis and severity.
- The new method allows for quick results in just 5 minutes while significantly reducing the amount of detection antibody used compared to conventional assays.